Show items per page
Elements: 18
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial Cahn, Pedro; Kaplan, Richard; Sax, Paul E; Squires, Kathleen; ... Calmy, Alexandra 2017
add to browser selection
Increased bioavailable vitamin B6 in field-grown transgenic cassava for dietary sufficiency Li, Kuan-Te; Moulin, Michael; Mangel, Nathalie; Albersen, Monique; ... Vanderschuren, Hervé 2015
add to browser selection
Neue Erkenntnisse zu Fumarsaureestern (Fumaderm((R))): Ergebnisse eines Experten-Workshops Mrowietz, Ulrich; Adamczyk, A.; Augustin, Matthias; Boehncke, Wolf-Henning; ... Neureither, M. 2011
add to browser selection
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir Lubomirov, Rubin; di Iulio, J.; Fayet, A.; Colombo, Sara; ... Telenti, A. 2010
add to browser selection
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability Ancrenaz, Virginie; Daali, Youssef; Fontana, Pierre; Besson, M.; ... Desmeules, Jules Alexandre 2010
add to browser selection
Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring Grandjean, Etienne Marc; Aubry, Jean-Michel 2009
add to browser selection
Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye Furrer, E.; Berdugo, Marianne; Stella, Cinzia; Behar-Cohen, Francine; ... Urech, David M. 2009
add to browser selection
P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone Kanaan, Mouna; Daali, Youssef; Dayer, Pierre; Desmeules, Jules Alexandre 2009
add to browser selection
Dermatopharmacokinetic prediction of topical drug bioavailability in vivo Herkenne, Christophe; Naik, Aarti; Kalia, Yogeshvar; Hadgraft, Jonathan; Guy, Richard H. 2007
add to browser selection
Pig ear skin ex vivo as a model for in vivo dermatopharmacokinetic studies in man Herkenne, Christophe; Naik, Aarti; Kalia, Yogeshvar; Hadgraft, Jonathan; Guy, Richard H. 2006
add to browser selection
Emerging strategies for the transdermal delivery of peptide and protein drugs Schuetz, Yannic; Naik, Aarti; Guy, Richard H.; Kalia, Yogeshvar 2005
add to browser selection
P-glycoprotein and surfactants: effect on intestinal talinolol absorption Bogman, Katrijn; Zysset, Yvonne; Degen, Lukas; Hopfgartner, Gerard; ... Drewe, Juergen 2005
add to browser selection
Rofecoxib interaction with oral anticoagulant acenocoumarol Girardin, François; Siegenthaler, Michèle Andrée; De Moerloose, Philippe; Desmeules, Jules Alexandre 2003
add to browser selection
Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man Alberti, Ingo; Kalia, Yogeshvar; Naik, Aarti; Guy, Richard H. 2001
add to browser selection
Assessment of topical bioavailability in vivo: the importance of stratum corneum thickness Kalia, Yogeshvar; Alberti, Ingo; Naik, Aarti; Guy, Richard H. 2001
add to browser selection
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects Weber, Cornelia; Schmitt, Rita; Birnboeck, Herbert; Hopfgartner, Gerard; ... Jones, Charles-Richard 1996
add to browser selection
Aqueous humor penetration of ofloxacin given by various routes von Gunten, S.; Lew, Daniel Pablo; Paccolat, F.; Vaudaux, Pierre; ... Leuenberger, P. M. 1994
add to browser selection
Peripheral inactivation of gentamicin Vaudaux, Pierre 1981